W. Roy Smythe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
W. Roy Smythe has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Imran Mohiuddin
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
3 shared publicationsMustafa K. Ozvaran
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
3 shared publicationsXiaobo X. Cao
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
3 shared publicationsJonathan C. Daniel
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
2 shared publicationsSteven D. Miller
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
2 shared publicationsAnthony L Estrera
Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA
1 shared publication
Latest Publications
- 30 September 2007
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 84 (3) , 982-986
Use of Aprotinin in Extrapleural Pneumonectomy: Effect on Hemostasis and Incidence of Complications
- 30 September 2007
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 84 (3) , 982-986
Use of Aprotinin in Extrapleural Pneumonectomy: Effect on Hemostasis and Incidence of Complications
- 31 October 2004
- Published by Elsevier in Journal of Surgical Research
- Vol. 121 (2) , 153-158
Gene therapy for sarcoma utilizing adenoviral transfer of the β-glucuronidase and bax genes and an anthracyline prodrug
- 31 October 2004
- Published by Elsevier in Journal of Surgical Research
- Vol. 121 (2) , 153-158
Gene therapy for sarcoma utilizing adenoviral transfer of the β-glucuronidase and bax genes and an anthracyline prodrug
- Open Access
- 1 May 2004
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 3 (5) , 545-550
Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma
Objective: Malignant pleural mesothelioma (MPM) is resistant to both conventional chemotherapy and apoptosis. The bcl-2 family proteins are major determinants of apoptotic homeostasis. MPM lines and tumors routinely overexpress the anti-apoptotic protein BCL-XL. We have previously shown that antisense inhibition of BCL-XL in MPM cells leads to apoptosis. We sought to determine whether antisense oligonucleotides directed at the bcl-xl gene product would augment response to a conventional chemotherapeutic agent in human mesothelioma cell lines.Methods: The human MPM cell lines REN and I-45 were exposed to two bcl-xl antisense oligonucleotides (15999, 16009) and one sense oligonucleotide (113529) construct at varying doses, followed by IC50 cisplatin. Cellular viability was assessed by a calorimetric assay, and apoptosis was evaluated by Hoechst staining, Annexin V staining, and sub-G1 fluorescence-activated cell sorter analysis. Western blot analysis of BCL-2 family proteins was performed following single agent and combined treatment. Isobologram mathematical analysis was used to determine whether or not combination therapies were additive or synergistic.Results: Cell viability was most affected with the 15999 antisense oligonucleotides plus IC50 cisplatin combination (70% of I-45 and 90% of REN cells killed), and apoptosis was markedly increased with this combination by all measures. Western blot demonstrated 15999 antisense oligonucleotides construct down-regulation of BCL-XL, but no further effect on expression of BCL-2 proteins with cisplatin. Isobologram analysis demonstrated 15999 + cisplatin synergistic effect.Conclusions: Exposure of human MPM cells to bcl-xl antisense oligonucleotides sensitizes human mesothelioma cells to the conventional chemotherapeutic agent cisplatin. Similar approaches using a combination of molecular and conventional treatment may have clinical utility for this tumor.
- 1 May 2004
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 3 (5) , 545-550
Open AccessAntisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma
Objective: Malignant pleural mesothelioma (MPM) is resistant to both conventional chemotherapy and apoptosis. The bcl-2 family proteins are major determinants of apoptotic homeostasis. MPM lines and tumors routinely overexpress the anti-apoptotic protein BCL-XL. We have previously shown that antisense inhibition of BCL-XL in MPM cells leads to apoptosis. We sought to determine whether antisense oligonucleotides directed at the bcl-xl gene product would augment response to a conventional chemotherapeutic agent in human mesothelioma cell lines.Methods: The human MPM cell lines REN and I-45 were exposed to two bcl-xl antisense oligonucleotides (15999, 16009) and one sense oligonucleotide (113529) construct at varying doses, followed by IC50 cisplatin. Cellular viability was assessed by a calorimetric assay, and apoptosis was evaluated by Hoechst staining, Annexin V staining, and sub-G1 fluorescence-activated cell sorter analysis. Western blot analysis of BCL-2 family proteins was performed following single agent and combined treatment. Isobologram mathematical analysis was used to determine whether or not combination therapies were additive or synergistic.Results: Cell viability was most affected with the 15999 antisense oligonucleotides plus IC50 cisplatin combination (70% of I-45 and 90% of REN cells killed), and apoptosis was markedly increased with this combination by all measures. Western blot demonstrated 15999 antisense oligonucleotides construct down-regulation of BCL-XL, but no further effect on expression of BCL-2 proteins with cisplatin. Isobologram analysis demonstrated 15999 + cisplatin synergistic effect.Conclusions: Exposure of human MPM cells to bcl-xl antisense oligonucleotides sensitizes human mesothelioma cells to the conventional chemotherapeutic agent cisplatin. Similar approaches using a combination of molecular and conventional treatment may have clinical utility for this tumor.
- 18 September 2003
- Published by Wiley in Seminars in Surgical Oncology
- Vol. 21 (3) , 196-204
Gene therapy of lung cancer
It is estimated that there will be 157,200 deaths from lung cancer in 2003. Current regimens of surgery, chemotherapy and radiation have not significantly changed overall 5-year survival rates for this disease. Thanks to intensive molecular studies over the last three decades, new targets for treatment have been identified, including replacement of tumor suppressor genes, prevention of angiogenesis and tumor growth, and regulation of programmed cell death. Promising advances have been made but obstacles still abound before effective use of these strategies at the patient bedside can occur. One area of concentration lies in developing more accurate and complete delivery of the therapeutic constructs. In the evolution of gene therapy approaches, from beginning theory to translational research, investigators in thoracic malignancies have played a leading role, utilizing a number of methods and delivery vehicles. The objective of this review is to discuss some of the major molecular targets available for manipulation in lung cancer, describe vectors and techniques currently used by thoracic researchers to deliver therapy, and provide the p53 model as an example of progression from bench research to clinical treatment.
- 18 September 2003
- Published by Wiley in Seminars in Surgical Oncology
- Vol. 21 (3) , 196-204
Gene therapy of lung cancer
It is estimated that there will be 157,200 deaths from lung cancer in 2003. Current regimens of surgery, chemotherapy and radiation have not significantly changed overall 5-year survival rates for this disease. Thanks to intensive molecular studies over the last three decades, new targets for treatment have been identified, including replacement of tumor suppressor genes, prevention of angiogenesis and tumor growth, and regulation of programmed cell death. Promising advances have been made but obstacles still abound before effective use of these strategies at the patient bedside can occur. One area of concentration lies in developing more accurate and complete delivery of the therapeutic constructs. In the evolution of gene therapy approaches, from beginning theory to translational research, investigators in thoracic malignancies have played a leading role, utilizing a number of methods and delivery vehicles. The objective of this review is to discuss some of the major molecular targets available for manipulation in lung cancer, describe vectors and techniques currently used by thoracic researchers to deliver therapy, and provide the p53 model as an example of progression from bench research to clinical treatment.
- Open Access
- 1 August 2003
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 76 (2) , 603-605
Primary lymphoepithelioma of the esophagus
- 1 August 2003
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 76 (2) , 603-605
Open AccessPrimary lymphoepithelioma of the esophagus
- 1 June 2002
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 123 (6) , 1191-1198
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
- 1 June 2002
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 123 (6) , 1191-1198
Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product
- 1 April 2002
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 9 (3) , 310-316
Phosphatase and Tensin Analog Gene Overexpression Engenders Cellular Death in Human Malignant Mesothelioma Cells via Inhibition of AKT Phosphorylation
- 1 April 2002
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 9 (3) , 310-316
Phosphatase and Tensin Analog Gene Overexpression Engenders Cellular Death in Human Malignant Mesothelioma Cells via Inhibition of AKT Phosphorylation
- 1 August 2001
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 8 (8) , 547-554
Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.
- 1 August 2001
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 8 (8) , 547-554
Significant augmentation of pro-apoptotic gene therapy by pharmacologic bcl-xl down-regulation in mesothelioma
Cancer Gene Therapy is the essential gene therapy resource for cancer researchers and clinicians, keeping readers up to date with the latest developments in gene therapy for cancer.